Ferkolj I - Search Results

1

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

Drobne D, Kurent T, Golob S, Švegl P, Rajar P, Hanžel J, Koželj M, Novak G, Smrekar N, Ferkolj I, Štabuc B. Drobne D, et al. Among authors: ferkolj i. Aliment Pharmacol Ther. 2019 Apr;49(7):880-889. doi: 10.1111/apt.15179. Epub 2019 Feb 19. Aliment Pharmacol Ther. 2019. PMID: 30784100

2

Success and safety of high infliximab trough levels in inflammatory bowel disease.

Drobne D, Kurent T, Golob S, Svegl P, Rajar P, Terzic S, Kozelj M, Novak G, Smrekar N, Plut S, Sever N, Strnisa L, Hanzel J, Brecelj J, Urlep D, Osredkar J, Homan M, Orel R, Stabuc B, Ferkolj I, Smid A. Drobne D, et al. Among authors: ferkolj i. Scand J Gastroenterol. 2018 Aug;53(8):940-946. doi: 10.1080/00365521.2018.1486882. Epub 2018 Jul 10. Scand J Gastroenterol. 2018. PMID: 29987967

3

Dendritic cell profiles in the inflamed colonic mucosa predict the responses to tumor necrosis factor alpha inhibitors in inflammatory bowel disease.

Smrekar N, Drobne D, Smid LM, Ferkolj I, Stabuc B, Ihan A, Kopitar AN. Smrekar N, et al. Among authors: ferkolj i. Radiol Oncol. 2018 Nov 26;52(4):443-452. doi: 10.2478/raon-2018-0045. Radiol Oncol. 2018. PMID: 30511938 Free PMC article.

4

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.

Hanžel J, Sever N, Ferkolj I, Štabuc B, Smrekar N, Kurent T, Koželj M, Novak G, Compernolle G, Tops S, Gils A, Drobne D. Hanžel J, et al. Among authors: ferkolj i. United European Gastroenterol J. 2019 Jul;7(6):741-749. doi: 10.1177/2050640619840211. Epub 2019 Mar 19. United European Gastroenterol J. 2019. PMID: 31316778 Free PMC article.

5

Diagnosing cytomegalovirus in patients with inflammatory bowel disease--by immunohistochemistry or polymerase chain reaction?

Zidar N, Ferkolj I, Tepeš K, Štabuc B, Kojc N, Uršič T, Petrovec M. Zidar N, et al. Among authors: ferkolj i. Virchows Arch. 2015 May;466(5):533-9. doi: 10.1007/s00428-015-1741-8. Epub 2015 Feb 21. Virchows Arch. 2015. PMID: 25701481

6

Fatal hemorrhage due to thrombosis and rupture of the portal vein and hepatic artery.

Ferkolj I, Vrh-Jermancic J, Stabuc B. Ferkolj I, et al. Wien Klin Wochenschr. 2009;121(15-16):537-9. doi: 10.1007/s00508-009-1179-6. Wien Klin Wochenschr. 2009. PMID: 19787325

7

Acute biliary pancreatitis: detection of common bile duct stones with endoscopic ultrasound.

Stabuc B, Drobne D, Ferkolj I, Gruden A, Jereb J, Kolar G, Mlinaric V, Mervic M, Repse A, Stepec S, Markovic S. Stabuc B, et al. Among authors: ferkolj i. Eur J Gastroenterol Hepatol. 2008 Dec;20(12):1171-5. doi: 10.1097/MEG.0b013e32830a9a31. Eur J Gastroenterol Hepatol. 2008. PMID: 18989141

8

CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease.

Ferkolj I, Ihan A, Markovic S. Ferkolj I, et al. Hepatogastroenterology. 2005 Jul-Aug;52(64):1128-33. Hepatogastroenterology. 2005. PMID: 16001645 Clinical Trial.

9

How to improve the safety of biologic therapy in Crohn's disease.

Ferkolj I. Ferkolj I. J Physiol Pharmacol. 2009 Dec;60 Suppl 7:67-70. J Physiol Pharmacol. 2009. PMID: 20388947 Free article. Review.

10

Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease.

Ferkolj I, Hocevar A, Golouh R, Dolenc Voljc M. Ferkolj I, et al. Acta Dermatovenerol Alp Pannonica Adriat. 2006 Dec;15(4):173-7. Acta Dermatovenerol Alp Pannonica Adriat. 2006. PMID: 17982610 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters